Literature DB >> 3657849

Membrane defects in paramyotonia congenita (Eulenburg).

F Lehmann-Horn1, R Rüdel, K Ricker.   

Abstract

Membrane potentials, current-voltage relationships, and component conductances were determined in resting excised external intercostal muscle fibers from five patients with paramyotonia congenita. At 37 degrees C all investigated parameters were normal. At 27 degrees C the resting potentials decreased to about -40 mV, and the fibers were inexcitable. At this stage the membrane currents were much larger than in normal fibers owing to increases in the membrane conductances for Na and Cl ions. The earlier finding that in the cold the Na permeability is abnormally large was confirmed. The Cl permeability was shown to be normal even in the cold. The decrease of the resting potential and the changes in the current-voltage relationship at 27 degrees C could be prevented by the use of the Na channel blocker tetrodotoxin (TTX) or by bathing the fibers in a Na-free solution. Our previous conclusion that the Cl conductance at 27 degrees C was also increased when TTX was present was not confirmed. Exposure of a muscle bundle to 7 mmol/l potassium did not lead to excessive depolarization and paralysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3657849     DOI: 10.1002/mus.880100709

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

1.  Mechanisms of cold sensitivity of paramyotonia congenita mutation R1448H and overlap syndrome mutation M1360V.

Authors:  Bahram Mohammadi; Nenad Mitrovic; Frank Lehmann-Horn; Reinhard Dengler; Johannes Bufler
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

Review 2.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

3.  Linkage data suggesting allelic heterogeneity for paramyotonia congenita and hyperkalemic periodic paralysis on chromosome 17.

Authors:  M C Koch; K Ricker; M Otto; T Grimm; K Bender; B Zoll; P S Harper; F Lehmann-Horn; R Rüdel; E P Hoffman
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

Review 4.  Structure, function and expression of voltage-dependent sodium channels.

Authors:  R G Kallen; S A Cohen; R L Barchi
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

5.  Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro.

Authors:  N Yang; S Ji; M Zhou; L J Ptácek; R L Barchi; R Horn; A L George
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker.

Authors:  H Lerche; R Heine; U Pika; A L George; N Mitrovic; M Browatzki; T Weiss; M Rivet-Bastide; C Franke; M Lomonaco
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

7.  The alpha-subunit of the skeletal muscle sodium channel is encoded proximal to Tk-1 on mouse chromosome 11.

Authors:  C Ambrose; S Cheng; B Fontaine; J H Nadeau; M MacDonald; J F Gusella
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 8.  Sodium channelopathies of skeletal muscle result from gain or loss of function.

Authors:  Karin Jurkat-Rott; Boris Holzherr; Michael Fauler; Frank Lehmann-Horn
Journal:  Pflugers Arch       Date:  2010-03-17       Impact factor: 3.657

9.  Cromakalim (BRL 34915) restores in vitro the membrane potential of depolarized human skeletal muscle fibres.

Authors:  A Spuler; F Lehmann-Horn; P Grafe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

10.  Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus.

Authors:  L J Ptacek; J S Trimmer; W S Agnew; J W Roberts; J H Petajan; M Leppert
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.